Most Primary Care Consumers Open To Alzheimer’s Blood-Based Biomarker Testing After Brief Education

Primary care consumers are broadly open to blood-based biomarker testing for Alzheimer’s disease once they receive even a brief explanation of what the tests involve. Prior to the short educational overview, 83.7% had never heard of the tests, and just 1.8% had ever taken one. Support for the tests increased after the educational overview. The overview did not name specific tests.

After receiving a brief education about the test, 76.8% thought it was very important to offer testing to people experiencing memory or thinking problems, and another 17.7% thought it was somewhat important to . . .